Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5

Most organisms rely on innate immune receptors to recognize conserved molecular structures from invading microbes. Two essential innate immune receptors, RIG-I and MDA5, detect viral double-stranded RNA in the cytoplasm. The inflammatory response triggered by these RIG-I-like receptors (RLRs) is one...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 5; p. 342
Main Authors Reikine, Stephanie, Nguyen, Jennifer B., Modis, Yorgo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.07.2014
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2014.00342

Cover

More Information
Summary:Most organisms rely on innate immune receptors to recognize conserved molecular structures from invading microbes. Two essential innate immune receptors, RIG-I and MDA5, detect viral double-stranded RNA in the cytoplasm. The inflammatory response triggered by these RIG-I-like receptors (RLRs) is one of the first and most important lines of defense against infection. RIG-I recognizes short RNA ligands with 5'-triphosphate caps. MDA5 recognizes long kilobase-scale genomic RNA and replication intermediates. Ligand binding induces conformational changes and oligomerization of RLRs that activate the signaling partner MAVS on the mitochondrial and peroxisomal membranes. This signaling process is under tight regulation, dependent on post-translational modifications of RIG-I and MDA5, and on regulatory proteins including unanchored ubiquitin chains and a third RLR, LGP2. Here, we review recent advances that have shifted the paradigm of RLR signaling away from the conventional linear signaling cascade. In the emerging RLR signaling model, large multimeric signaling platforms generate a highly cooperative, self-propagating, and context-dependent signal, which varies with the subcellular localization of the signaling platform.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Anton G. Kutikhin, Russian Academy of Medical Sciences, Russia
Reviewed by: Christian Muenz, University of Zurich, Switzerland; Gaya Amarasinghe, Washington University School of Medicine, USA; Arseniy E. Yuzhalin, University of Oxford, UK
This article was submitted to Tumor Immunity, a section of the journal Frontiers in Immunology.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2014.00342